{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T15:10:37Z","timestamp":1785337837202,"version":"3.55.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurodevelop Disord"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>There have been increasing numbers of clinical trials of medications for fragile X syndrome (FXS) in recent years, many targeted at proposed underlying cellular or circuit based mechanisms. As yet none of these have led to widespread changes in clinical practice. Genetic therapies represent a different therapeutic approach, which aim to address the genetic mechanisms by which FXS arises. Although not yet moving into human studies in FXS, this is an area of increasing research importance in neurodevelopmental conditions more broadly. It is important that families affected by FXS get the chance to give their views about future genetic therapies, given the potential controversies around genetic therapies.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>We developed a questionnaire to capture caregiver views around gene therapy in FXS. The questionnaire was developed alongside a group of parents \/ caregivers of a child with FXS to ensure the language used was appropriate and that it would allow a variety of views to be captured. The questionnaire contained questions around current knowledge of gene therapy, what families think of gene therapy and their views on gene therapy trials taking place. Responses were analysed by thematic analysis carried out by two of the authors with data from the questionnaires being grouped into themes and subthemes.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>The questionnaire was completed by 195 individuals who are parents of, or who care for, someone with FXS. Respondents were primarily from the UK (60.5%) and the Americas (22.1%). The majority of dependants were male (86%).<\/jats:p>\n            <jats:p>Responses showed a strong interest from the Fragile X community in gene therapy trials taking place, with themes emerging around quality of life, outcomes and feelings. Hope for positive change was balanced against caution about unintended consequences, the newness of the treatment and tolerability.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>Overall, caregivers felt hopeful, excited and interested in the prospect of gene therapy potentially providing a new treatment option, but there was some trepidation about the potential effects. Taking caregiver views into account will help inform decisions around the development and testing of any future genetic interventions.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s11689-025-09629-1","type":"journal-article","created":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T09:52:57Z","timestamp":1756720377000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Preliminary perspectives on gene therapy in fragile X syndrome: a caregiver view"],"prefix":"10.1186","volume":"17","author":[{"given":"Sarah E. A.","family":"Eley","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sydni","family":"Weissgold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew C.","family":"Stanfield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,1]]},"reference":[{"key":"9629_CR1","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1097\/DBP.0b013e318272dcbc","volume":"33","author":"DB Bailey Jr","year":"2012","unstructured":"Bailey DB Jr, Raspa M, Bishop E, Mitra D, Martin S, Wheeler A, Sacco P. Health and economic consequences of fragile X syndrome for caregivers. Journal of Developmental & Behavioral Pediatrics. 2012;33:705\u201312.","journal-title":"Journal of Developmental & Behavioral Pediatrics"},{"key":"9629_CR2","doi-asserted-by":"publisher","first-page":"147","DOI":"10.5582\/irdr.2014.01025","volume":"3","author":"T Chechi","year":"2014","unstructured":"Chechi T, Siyahian S, Thairu L, Hagerman R, Lozano R. Participation of underrepresented minority children in clinical trials for Fragile X syndrome and other neurodevelopmental disorders. Intractable & rare diseases research. 2014;3:147\u201352.","journal-title":"Intractable & rare diseases research"},{"key":"9629_CR3","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1111\/jar.13069","volume":"36","author":"J Coleman","year":"2023","unstructured":"Coleman J, Thompson T, Riley K, Allen K, Michalak C, Shields R, Berry-Kravis E, Hessl D. The comparison of expressed emotion of parents of individuals with fragile X syndrome to other intellectual disabilities. J Appl Res Intellect Disabil. 2023;36:394\u2013404.","journal-title":"J Appl Res Intellect Disabil"},{"key":"9629_CR4","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1016\/j.paed.2020.08.007","volume":"30","author":"H Crawford","year":"2020","unstructured":"Crawford H, Abbeduto L, Hall SS, Hardiman R, Hessl D, Roberts JE, Scerif G, Stanfield AC, Turk J, Oliver C. Fragile X syndrome: an overview of cause, characteristics, assessment and management. Paediatr Child Health. 2020;30:400\u20133.","journal-title":"Paediatr Child Health"},{"key":"9629_CR5","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1111\/jir.12605","volume":"63","author":"CS D'amanda","year":"2019","unstructured":"D\u2019amanda CS, Peay HL, Wheeler AC, Turbitt E, Biesecker BB. Fragile X syndrome clinical trials: exploring parental decision-making. J Intellect Disabil Res. 2019;63:926\u201335.","journal-title":"J Intellect Disabil Res"},{"key":"9629_CR6","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1111\/jir.12779","volume":"64","author":"SEA Eley","year":"2020","unstructured":"Eley SEA, Mckechanie AG, Campbell S, Stanfield AC. Facilitating individuals and families affected by fragile X syndrome to participate in medication trials. J Intellect Disabil Res. 2020;64:864\u201374.","journal-title":"J Intellect Disabil Res"},{"key":"9629_CR7","volume-title":"Physical and behavioural characteristics of fragile X syndrome","author":"R Hagerman","year":"2003","unstructured":"Hagerman R. Physical and behavioural characteristics of fragile X syndrome. Educating Children with Fragile X Syndrome: Routledge; 2003."},{"key":"9629_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/nrdp.2017.65","volume":"3","author":"RJ Hagerman","year":"2017","unstructured":"Hagerman RJ, Berry-Kravis E, Hazlett HC, Bailey DB, Moine H, Kooy RF, Tassone F, Gantois I, Sonenberg N, Mandel JL. Fragile X syndrome. Nature reviews Disease primers. 2017;3:1\u201319.","journal-title":"Nature reviews Disease primers"},{"key":"9629_CR9","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.ridd.2018.02.020","volume":"76","author":"RL Hardiman","year":"2018","unstructured":"Hardiman RL, Mcgill P. How common are challenging behaviours amongst individuals with fragile X syndrome? A systematic review. Res Dev Disabil. 2018;76:99\u2013109.","journal-title":"Res Dev Disabil"},{"key":"9629_CR10","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/j.omtm.2021.06.013","volume":"22","author":"AW Hooper","year":"2021","unstructured":"Hooper AW, Wong H, Niibori Y, Abdoli R, Karumuthil-Melethil S, Qiao C, Danos O, Bruder JT, Hampson DR. Gene therapy using an ortholog of human fragile X mental retardation protein partially rescues behavioral abnormalities and EEG activity. Molecular Therapy Methods & Clinical Development. 2021;22:196\u2013209.","journal-title":"Molecular Therapy Methods & Clinical Development"},{"key":"9629_CR11","doi-asserted-by":"crossref","unstructured":"Johnson D, Clark C, Hagerman R. Targeted treatments for fragile X syndrome. Drug Dev Psych. Springer. 2023;30:225\u201353.","DOI":"10.1007\/978-3-031-21054-9_10"},{"key":"9629_CR12","volume-title":"Cognitive enhancers, intellectual disability, and personal identity: emerging ethical issues","author":"F Jotterand","year":"2020","unstructured":"Jotterand F, Mccurdy J, Elger B. Cognitive enhancers, intellectual disability, and personal identity: emerging ethical issues. Rosenberg\u2019s Molecular and Genetic Basis of Neurological and Psychiatric Disease: Elsevier; 2020."},{"key":"9629_CR13","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1542\/peds.2013-4301","volume":"134","author":"SA Kidd","year":"2014","unstructured":"Kidd SA, Lachiewicz A, Barbouth D, Blitz RK, Delahunty C, Mcbrien D, Visootsak J, Berry-Kravis E. Fragile X syndrome: a review of associated medical problems. Pediatrics. 2014;134:995\u20131005.","journal-title":"Pediatrics"},{"key":"9629_CR14","doi-asserted-by":"publisher","unstructured":"Kousparou CA. Genetic treatments for rare neurodegenerative disorders. In Rare Neurodegenerative Disorders - New Insights. Intechopen. 2024. https:\/\/doi.org\/10.5772\/intechopen.11260.","DOI":"10.5772\/intechopen.11260"},{"key":"9629_CR15","unstructured":"Mckechanie AG, Stanfield AC, Fisher L, Morgan CL, Jones BI, Cooper A, Conway P. What can we learn about health and healthcare from large-scale, routinely-acquired data in the United Kingdom: Studies in Fragile X Syndrome. Bali: 26th International Society for the Study of Behavioural Phenotypes Research Symposium; 2024;65."},{"key":"9629_CR16","doi-asserted-by":"crossref","unstructured":"Percy AK, Ananth A, Neul JL. Rett syndrome: the emerging landscape of treatment strategies. CNS drugs. 2024;38(11):851\u201367","DOI":"10.1007\/s40263-024-01106-y"},{"key":"9629_CR17","doi-asserted-by":"crossref","unstructured":"Ramsey K, Lafleur M, Robinson K, Borgstrom M, Ryan A, Narayanan V, Schaibley V. Family and caregiver perspectives on gene therapy for rett syndrome. Rare. 2024;2:100045.","DOI":"10.1016\/j.rare.2024.100045"},{"key":"9629_CR18","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1007\/s10897-017-0111-x","volume":"26","author":"V Reines","year":"2017","unstructured":"Reines V, Charen K, Rosser T, Eisen A, Sherman SL, Visootsak J. Parental perspectives on pharmacological clinical trials: a qualitative study in Down syndrome and fragile X syndrome. J Genet Couns. 2017;26:1333\u201340.","journal-title":"J Genet Couns"},{"key":"9629_CR19","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1080\/17518423.2016.1259274","volume":"21","author":"A Sterling","year":"2018","unstructured":"Sterling A, Warren SF. Parenting of children with Down syndrome compared to fragile X syndrome. Dev Neurorehabil. 2018;21:64\u20137.","journal-title":"Dev Neurorehabil"},{"key":"9629_CR20","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1080\/14656566.2024.2323605","volume":"25","author":"LV Watkins","year":"2024","unstructured":"Watkins LV, Moon S, Burrows L, Tromans S, Barwell J, shankar, R. Pharmacological management of fragile X syndrome: a systematic review and narrative summary of the current evidence. Expert Opinion on Pharmacotherapy. 2024;25:301\u201313.","journal-title":"Expert Opinion on Pharmacotherapy"},{"key":"9629_CR21","doi-asserted-by":"publisher","first-page":"18","DOI":"10.3390\/brainsci9020018","volume":"9","author":"JD Weber","year":"2019","unstructured":"Weber JD, Smith E, Berry-Kravis E, Cadavid D, Hessl D, Erickson C. Voice of people with fragile X syndrome and their families: reports from a survey on treatment priorities. Brain Sci. 2019;9:18.","journal-title":"Brain Sci"},{"key":"9629_CR22","doi-asserted-by":"crossref","unstructured":"Wong H, Hooper AW, Kang HR, Lee SJ, Zhao J, Sadhu C, Rawat S, Gray SJ, Hampson DR. CNS-dominant human FMRP isoform rescues seizures, fear, and sleep abnormalities in Fmr1-KO mice. JCI insight. 2023;8(11):e169650.","DOI":"10.1172\/jci.insight.169650"}],"container-title":["Journal of Neurodevelopmental Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s11689-025-09629-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s11689-025-09629-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s11689-025-09629-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T01:13:04Z","timestamp":1757466784000},"score":1,"resource":{"primary":{"URL":"https:\/\/jneurodevdisorders.biomedcentral.com\/articles\/10.1186\/s11689-025-09629-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,1]]},"references-count":22,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["9629"],"URL":"https:\/\/doi.org\/10.1186\/s11689-025-09629-1","relation":{},"ISSN":["1866-1955"],"issn-type":[{"value":"1866-1955","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,1]]},"assertion":[{"value":"16 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was reviewed by Edinburgh medical school research ethics committee (EMREC)\u00a0with favourable opinion granted on 25th April 2024 (REC Reference: 24-EMREC-011). Study participation was voluntary and confidential. Data collection occurred between May and July 2024.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"ACS has received grants and consultancy fees paid to the University of Edinburgh from Novartis, Roche, Shionogi, Enthorin Therapuetics and Zynerba.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"55"}}